Upadacitinib
Janus Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: ABT-494, rinvoq, upadacitinib hydrate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Upadacitinib is an onp drug in the Janus Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Janus Kinase Inhibitors. DrugCentral lists 26 molecular targets, including JAK1, JAK2 and ROCK2. Recorded indications include Ankylosing spondylitis, Atopic dermatitis, Crohn's disease and Nonradiographic axial spondyloarthritis.
- Approval status: onp (first approved 2019 by the FDA).
- Drug class: Janus Kinase Inhibitor.
- Mechanism of action: Janus Kinase Inhibitors.
- Molecular targets: JAK1, JAK2, ROCK2 and Jak2 (26 listed in DrugCentral).
- Indications: Ankylosing spondylitis, Atopic dermatitis, Crohn's disease, Nonradiographic axial spondyloarthritis and Psoriatic arthritis and others.
- ATC code: L04AF03 (Janus-associated kinase (JAK) inhibitors).
- Molecular formula: C17H19F3N6O; molecular weight 380.38 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (7)
- Ankylosing spondylitis
- Atopic dermatitis
- Crohn's disease
- Nonradiographic axial spondyloarthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Ulcerative colitis
Mechanism & targets
| Mechanism of action (MoA) | Janus Kinase Inhibitors |
|---|---|
| Established pharmacologic class | Janus Kinase Inhibitor |
Molecular targets (26)
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2020-01-23 | PMDA | — | AbbVie GK | |
| 2019-12-16 | EMA | — | AbbVie Deutschland GmbH & Co. KG | |
| 2019-08-16 | FDA | — | ABBVIE INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AF03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CYP2D6
- FDA label: CYP2D6 · No Clinical PGx
- HCSC label: CYP2D6 · No Clinical PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Therapy interrupted | 4928.7 |
| COVID-19 | 1091.7 |
| Product residue present | 832.8 |
| Illness | 822.6 |
| Acne | 799.2 |
| Herpes zoster | 798.1 |
| Intentional dose omission | 415.5 |
| Drug ineffective | 284.7 |
| Surgery | 284.3 |
| Urinary tract infection | 270.8 |
| Eczema herpeticum | 244.5 |
| Therapy cessation | 243.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Upadacitinib is on its molecule page.
| Molecular formula | C17H19F3N6O |
|---|---|
| Molecular weight | 380.38 g/mol |
| CAS number | 1310726-60-3 |
| InChIKey | WYQFJHHDOKWSHR-MNOVXSKESA-N |
| PubChem CID | 58557659 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Upadacitinib used for?
DrugCentral lists the following indications for Upadacitinib: Ankylosing spondylitis, Atopic dermatitis, Crohn's disease, Nonradiographic axial spondyloarthritis, Psoriatic arthritis, Rheumatoid arthritis and Ulcerative colitis.
How does Upadacitinib work?
Upadacitinib is classified as Janus Kinase Inhibitors; its molecular targets in DrugCentral include JAK1 (inhibitor), JAK2 (inhibitor), ROCK2 and Jak2.
When was Upadacitinib first approved?
Upadacitinib was first approved by the FDA in 2019.
What drug class does Upadacitinib belong to?
Upadacitinib is in the Janus Kinase Inhibitor class.
What is the chemical formula of Upadacitinib?
Upadacitinib has the molecular formula C17H19F3N6O and a molecular weight of 380.38 g/mol.
Browse: all drugs starting with U · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5346 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3622821 — compound record and bioactivity
- PubChem CID 58557659 — chemical identifiers
- DrugBank DB15091 — drug record
- FDA UNII 4RA0KN46E0 — substance identity
- DailyMed: FDA labels for Upadacitinib — current prescribing information (label search)
- UniProt P23458 (JAK1) — target protein
- UniProt O60674 (JAK2) — target protein
- UniProt O75116 (ROCK2) — target protein
- UniProt Q13464 (ROCK1) — target protein
- UniProt P35968 (KDR) — target protein
- UniProt O14976 (GAK) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.